Washington Biotech Newsletter Archives
At Washington Biotech we are continuously expanding, improving and upgrading our in vivo and in vitro services. This is what drives our scientists and this is what our clients count on.  And it is this continuous commitment to innovation that sets us apart as the Preclinical CRO "Partner of Choice".
 
We keep our valued clients and the biomedical research community in general apprised of our latest developments through our E-Newsletter.
 
We know the importance of timely value. For this reason we issue our Newsletter in "real-time", i.e. as soon as new or modified services are brought online. 
 
If you would like to receive the most up-to-date information on our services, please join our mailing list. The information you receive may be important for your next study. 
 
For your information, here is a Quick View of some archived Newsletters. Thank you for your interest.
 
 
  • Reference Drugs: Head & Neck Cancer Model (Fa Du)  (2/11/2015)
  • It is important to establish reference drugs as the positive control with efficacy for tumor growth inhibition. . .

  • Intra-articular Gout Model in Rat  (11/22/2014)
  • WBI provides a reliable and direct in vivo model for determining the efficacy of test compounds in treating symptoms of gout. . .

  • Rapid Turnaround PK Services  (10/21/2014)
  • With over 25 years of experience, WBI offers PK services with: rapid start-up; rapid results; and economical pricing.

  • CON A-Induced Hepatitis Model  (9/2/2014)
  • Autoimmune Hepatitis (AIH) is a chronic inflammatory disease of the liver characterized by breakdown of self-tolerance leading to the appearance of autoantibodies (ANA, SMA, other) . . .

  • Inflammatory Bowel Disease (IBD) In Vivo Models  (6/24/2014)
  • WBI has many years of experience with in vivo TNBS-induced and Indomethacin-induced rodent models with reliable results for both prophylactic and therapeutic dosing.

  • Optimizing your disease model study  (5/1/2014)
  • To fully benefit from your disease model study, preliminary in vivo analysis can make a significant difference in both time and money invested. . .

  • SLE Mouse Model   (4/17/2014)
  • Pristane-induced lupus is a well-established model of murine lupus with a demonstrated usefulness for evaluation of new therapies. . .

  • Psoriasis Model  (2/26/2014)
  • IMQ-induced psoriasis is a useful mouse model for evaluation of new therapies for psoriasis and dermatitis. . .

  • Bacterial Infection Studies  (10/16/2013)
  • In Vivo Models for Test Material Anti-infection Efficacy . . .

  • Xenograft Services  (9/16/2013)
  • Washington Biotech provides cost-efficient quality services for efficacy studies of test compounds and biologics. . .

  • New Drug Development: Toxicity Safety Profile  (8/5/2013)
  • In Vivo toxicity evaluation is a basic first step in new drug development. Washington Biotechnology provides rapid and comprehensive assessment of toxicity in rodents, guinea pigs or rabbits, tailored to each Client's needs. . .

  • New Drug Development: Safety Profiles  (6/7/2013)
  • Rising concerns about drug side effects indicate the value of broadening the safety profiles for new compounds beyond the basic toxicity assessment. . .

  • EAE Models for Multiple Sclerosis  (5/21/2013)
  • Washington Biotechnology, Inc., a leader in In Vivo preclinical testing, has full services for analysis of test article efficacy in EAE Models of human multiple sclerosis (human demyelinating disease). . .

  • OVA-induced Arthritis Rabbit Model  (4/25/2013)
  • Experience with intra-articular injections is an important requirement for success with the Ovalbumin-Induced Arthritis (OIA) rabbit model. Our scientists have long experience with this model which affords the advantage of synovial fluid measures at convenient volumes. . .

  • Ear Edema Mouse Models  (4/11/2013)
  • Ear edema models in mice are sensitive and reliable tests for anti-inflammatory activity of topically applied materials. Plant extracts, compounds, oils, and ointments with potential anti-inflammatory activity can be rapidly assessed in these non-invasive tests. . .

  • Indomethacin-induced IBD Model  (3/29/2013)
  • This model, also referred to as Small Intestine Injury, is a valuable model for investigation of treatments for Crohn’s Disease which mainly affects the last part of the Small Intestine (terminal ileum). . .

  • Pancreatitis & Nephritis In Vivo Models  (3/5/2013)
  • Caerulein-induced acute pancreatitis in Balb/c mice; PA-induced Nephritis Model (rat); and Antibody-induced Nephritis Model (rat). . .

  • Head and Neck Cancers  (2/19/2013)
  • Head and Neck Cancers are a group of biologically similar cancers that start predominantly in the lip, mouth, nasal cavity, sinuses and larynx. Cultured human cell lines FaDu and A253 reliably provide consistent and rapid tumor growth in athymic nude mice. . .

  • Bacterial Infection  (2/6/2013)
  • Washington Biotech has the facilities to culture many different types of pathogenic bacteria for the evaluation of the efficacy of potential antibiotics in rodent models. The bacteria are administered by various routes to model a variety of disease states from food poisoning to lung infection to burn infections. . .

  • Rodent/Rabbit Combo-testing for Arthritis  (1/16/2013)
  • for additional assurance of test material efficacy. . . Because no single test is definitive in predicting efficacy for treatment of humans the importance of results from animal models in more than one species is recognized. . .

Washington Biotechnology, Inc.
6200 Seaforth Sreet
Baltimore, Maryland 21224
U.S.A. 

+1-410-633-9210
Keep informed . . . .